Author

Mia S. Donald-Paladino

Fred Hutch Cancer CenterORCID 0009-0004-9711-7180Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1

Frequent Co-Authors

Behnam NabetiD· 2 shared Saurav KumariD· 2 shared Alex Shida· 1 shared Alexander Joel FederationiD· 1 shared Ana María Fernández‐EscamillaiD· 1 shared Andrea Gutierrez· 1 shared Brian CoventryiD· 1 shared Bulat FaezoviD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Behnam NabetORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivPreprintJul 13, 2026

De novo design of selective kinase modulators

Magnus S. Bauer, Saurav Kumar, Mia S. Donald-Paladino…·David A. Baker

This study designs genetically encoded miniproteins to modulate FAK kinase activity, showing they can inhibit or activate FAK in vitro and in cells, and adapt them to target other kinases.

DOI 10.64898/2026.07.10.737808

protein structureexperimental assay

𝕏 PostBluesky

Cancer BiologyRSC Chemical BiologyPeer-reviewedJan 1, 2026

Development of PROTACs for targeted degradation of oncogenic TRK fusions

Saurav Kumar, Jiewei Jiang, Mia S. Donald-Paladino…·Behnam Nabet

This paper develops PROTACs to degrade oncogenic TRK fusions, showing improved efficacy compared to traditional inhibitors.

3 citationstop 4%

humanexperimental assay

𝕏 PostBluesky